We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Show more
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion...
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAN DIEGO, April 23, 2024 SAVITRI™ Study Met Primary Endpoint with...
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs PR Newswire TOKYO, April 22, 2024 TOKYO...
− ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease...
FY23 Investment Brings Program Total to Nearly $55 Million, Welcoming Eight New Grant Partners Company Continues to Advance Equity in Under-Resourced Communities with a Focus on Nutrition and...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire DUBAI, UAE, March 27, 2024 Takeda's 'In Their Shoes' initiative illuminates the daily...
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE PR Newswire DUBAI, UAE, March 27, 2024 Takeda's 'In Their Shoes' initiative illuminates the daily...
Takeda (TOKYO:4502/NYSE:TAK) a annoncé aujourd’hui que son conseil d’administration a décidé le 26 mars 2024 (CET) de proposer des candidats au conseil d’administration lors de la 148e assemblée...
Takeda (TOKYO:4502/NYSE:TAK) gab heute bekannt, dass sein Vorstand am 26. März 2024 (MEZ) beschlossen hat, Kandidaten für den Vorstand auf der 148. ordentlichen Hauptversammlung der Aktionäre am...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions